Lv1
70 积分 2024-11-06 加入
Multivalent, asymmetric IL-2–Fc fusions show enhanced selectivity for regulatory T cells
2个月前
已完结
New therapeutic strategies based on biasing IL-2 mutants for cancers and autoimmune diseases
2个月前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25CD8 T cells++
3个月前
已完结
Anti-Protein-Adsorption Nano-Proteolysis Targeting Chimeras as a Potent Platform for Efficient Programmed Cell Death Ligand 1 Degradation
4个月前
已完结
A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930)
5个月前
已完结
A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930)
5个月前
已完结
Immune agonist antibodies face critical test
5个月前
已完结
Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors
5个月前
已完结
Bivalent OX40 Aptamer and CpG as Dual Agonists for Cancer Immunotherapy
5个月前
已完结
Development and characterization of a novel anti-OX40 antibody for potent immune activation
5个月前
已完结
皖公网安备34019202002308
